Else Nutrition Expected to Benefit from FDA Regulatory Progress on Infant Formula Protein Standards

Updated FDA Framework Bolsters Scientific Validation Pathway for Else's Plant‑Based Formula and Accelerates U.S. Commercialization Potential VANCOUVER, BC, March 10, 2026 /PRNewswire/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL) ("Else" or the "Company"), a pioneer in whole-food plant-based, non-soy, non-dairy nutrition for early childhood nutrition, today announced that the U.S. Food and Drug Administration (FDA) has formally listed Protein Efficiency Ratio (PER) Rat Bioassay Study Guidance as an active topic within its Foods Program regulatory agenda.